Antibiotics - Global Trends

Antibiotics - Global Trends

Long-term growth in the global antibiotics market would be affected by two major factors - antibiotic resistance and generic competition. Antibiotic resistance, which compels reduction in the usage of antibiotics, represents the primary market inhibitor. In recent times, there has been a decline in antibiotic prescriptions for respiratory related infections. Another factor that could have a strong bearing on the market is the rising generic competition.

These and other market data and trends are presented in "Antibiotics: Global Trends" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

ANTIBIOTICS BMR-1063


CONTENTS


1. METHODOLOGY 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Quantitative Techniques & Reporting Level 3

2. GLOBAL MARKET OVERVIEW AND OUTLOOK 4
Antibiotic Resistance and Generic Competition to Impact Long
Term Growth 4

3. MARKET DYNAMICS 4
Anti-Bacterials Segment Drives Global Anti-Infectives Market 4
Antibiotic Resistance - A Primary Growth Inhibitor 5
Antibiotic-Resistant Bacteria by Type 5
Patent Expiries Commoditize Antibiotics 6
Patent Expiries of Leading Drugs in the Current and Future 6
Anti-MRSA Antibiotics Find Their Way 6
Key Antibiotics in Pipeline 7

4. COMPETITION 7
Highly Competitive Market 7
GlaxoSmithKline - The Undisputed Leader of Penicillin Market 8
GlaxoSmithKline Leads Cephalosporin Market 9
Pfizer Dominates Macrolides Market 9
Levaquin/Tavanic - The Most Preferred Quinolone Antibiotic 10
Merck Rules Carbapenems Market 11

5. PRODUCT FACTS 11
Penicillin 11
Cephalosporins 12
Macrolides 12
Quinolones 12
Carbapenems 12
Other Antibiotics 12
Aminoglycosides 12
Tetracyclines 13
Sulfonamides 13
Mupirocin 13
Glycopeptides 13
Synercid 13
Oxazolidinones 13
Linezolid 14

6. RESEARCH FINDINGS 14
Cephalosporins Effective when Compared to Penicillin 14
FDA Bans Baytril Antibiotic for Chickens 14
Erythromycin Along with Some Specific Drugs Increase Risk of
Sudden Death 15
Rise in Usage of Quinolones for Urinary Tract Infections Leads
to Drug Resistance 15

7. CORPORATE DEVELOPMENTS 15
3i to Buy Alpharma Unit 15
NCPC to Acquire Stake in DSM’s Antibiotics Division 16
ULL Establishes New Antibiotics Unit in Himachal Pradesh 16
Biocat to Expand Presence in the Indian Market 16
PRWT Acquires Cherokee Chemical Unit from Merck 16
CSPC Joins Hands with Indonesian Firms 16
MIT Scientists Develop a New Antibiotic, Rhodostreptomycin 17
Watson Pharma Introduces Biaxin XL’s Generic Version 17
MiddleBrook Obtains NDA Approval for MOXATAG™ 17
Nisshin-Kyorin to Merge with Kyorin Pharmaceutical 17
Schering-Plough Acquires Organon BioSciences 17
GSK & Anacor Partner for Boron Chemistry- Based Antibiotics
and Antivirals 18
Iroko Bags Canadian Rights to Vancocin® 18
Cubist Licenses CUBICIN Rights to Merck 19
Sagent Partners with Astral to Develop Injectable Antibiotics 19
MR Healthcare to Manufacture New Antibiotics & Medicines 19
Livzon Synthetic to Acquire Antibiotic Intermediate from Jiaozuo 19
C&O Pharmaceutical to Distribute Meiact in China 20
Bioton Signs Deal to Market Antibiotics in Russia 20
Toyama Gains Marketing Approval for Geninax® in Japan 20
Forest Laboratories Acquires Cerexa 20
Oscient Modifies Licensing Agreement With LG Life Sciences 20
Orchid Sign Licensing & Distribution Pact With Actavis 21
Forest Laboratories Revokes Partnership With Replidyne 21
SRI and Blanca Collaborate To Develop & Test Carbacephem 21
AstraZeneca To Expand Research Center for Antibiotics 21
Jade Pharmaceutical Begins Levofloxacin’s Production in China 22
Reyoung To Start Antibiotic Production at New Facility 22
Toyama Begins T-705 Clinical Trials 22
SmPC For Sanofi-Aventis’ Ketek® Updated 22
Lupin Receives Approval for Cefpodoxime Proxetil Antibiotic
Tablets in France 22
Antibiotice Plans To Infuse Funds for Antibiotics Production 23
UAE Approves Pfizer’s Zithromax SD 23
Toyama Launches New Garenoxacin Quinolone Antibiotic 23
Wockhardt to Introduce Cefprozil in the US 23
MSD India Launches Invanza in India 24
Orchid Chemicals to Introduce Three New Drugs in the US 24
DUSA Pharmaceuticals Releases ClindaReach™ 24
Mylan Releases Cipro’s Generic Version 24
Macrolide Antibiotic Developed in the US 24
University of Michigan Devises NMR Spectroscopy For Antibiotics 24
Glycopeptide-Cephalosporin Antibiotics Developed in the US 25
Neosil Tests NEO 101 Antibiotic 25
New Antibiotic Developed By Canadian Inventors 25
Abbott Canada Releases FACTIVE® Antibiotic Tablets In Canada 25
Penicillin Binding Protein Found In Japan 25
Venus Remedies Releases Mucomelt-Forte 25
J&JPRD Seeks FDA Approval for Doripenem Antibiotic 25
J&JPRD Seeks FDA Approval for Investigational Antibiotic,
Ceftobiprole 26
GSK Receives Approval for ALTARGO® in Europe 26
APL Receives FDA Approval for Cefpodoxime Proxetil 26
Cubist Receives Approval to Market CUBICIN in Canada 26
Cubist Obtains Approval to Market CUBICIN for Added
Indications in EU 27
Cubist Gains Approval for CUBICIN in Taiwan and South Korea 27
Cethromycin Achieves FDA’s Orphan Drug Designation 27

8. MAJOR PLAYERS 28
Abbott Laboratories (USA) 28
Bayer HealthCare AG (Germany) 28
Bristol-Myers Squibb Co. (USA) 28
Cubist Pharmaceuticals, Inc. (USA) 29
Daiichi Sankyo Company, Limited (Japan) 29
Eli Lilly and Co. (USA) 29
GlaxoSmithKline Plc (UK) 30
Johnson & Johnson (USA) 30
Kyorin Pharmaceutical Co., Ltd. (Japan) 31
LG Life Sciences Limited (Korea) 31
MiddleBrook™ Pharmaceuticals, Inc. (USA) 31
Novartis AG (Switzerland) 32
Pfizer Inc. (USA) 32
Pliva d.d. (Croatia) 32
Roche (Switzerland) 33
Sanofi-Aventis SA (France) 33
Takeda Pharmaceutical Company, Ltd. (Japan) 33
Toyama Chemical Co., Ltd. (Japan) 34
Wyeth Pharmaceuticals, Inc. (USA) 34

9. GLOBAL MARKET ANALYTICS 34

10. THE UNITED STATES 40
Competition 41

11. CANADA 42

12. JAPAN 43

13. EUROPE 44

a. France 46

b. Germany 48

c. Italy 49

d. The United Kingdom 50

e. Spain 51

f. Rest of Europe 52

14. ASIA-PACIFIC 53
India 53
Rising Prices of Penicillin G to Affect Antibiotics Production 53

15. REST OF WORLD 54


EXHIBITS

Table 1: Percentage Breakdown of Leading Antibiotics
Manufacturer Value Sales in the World - 2006

Table 2: Percentage Breakdown of Leading Antibiotics
Manufacturers within Penicillin Class in the World - 2006

Table 3: Percentage Breakdown of Leading Antibiotics
Manufacturers within Cephalosporin Class in the World - 2006

Table 4: Percentage Breakdown of Leading Antibiotics
Manufacturers within Macrolide Class in the World - 2006

Table 5: Percentage Breakdown of Leading Antibiotics
Manufacturers within Quinolone Class in the World - 2006

Table 6: Percentage Breakdown of Leading Antibiotics
Manufacturers within Carbapenem Class in the World - 2006

Table 7: Global Antibiotics Market by Region for the Period
2007-2015 (Sales in US$ Million)

Table 8: Percentage Breakdown of Global Antibiotics Market by
Region for the Years 2008 & 2012

Table 9: Global Penicillin Market by Region for the Period
2007-2015 (Sales in US$ Million)

Table 10: Percentage Breakdown of Global Penicillin Market by
Region for the Years 2008 & 2012

Table 11: Global Cephalosporin Market by Region for the Period
2007-2015 (Sales in US$ Million)

Table 12: Percentage Breakdown of Global Cephalosporin Market
by Region for the Years 2008 & 2012

Table 13: Global Macrolide Market by Region for the Period
2007-2015 (Sales in US$ Million)

Table 14: Percentage Breakdown of Global Macrolide Market by
Region for the Years 2008 & 2012

Table 15: Global Quinolones Market by Region for the Period
2007-2015 (Sales in US$ Million)

Table 16: Percentage Breakdown of Global Quinolones Market by
Region for the Years 2008 & 2012

Table 17: Global Carbapenems Market by Region for the Period
2007-2015 (Sales in US$ Million)

Table 18: Percentage Breakdown of Global Carbapenems Market by
Region for the Years 2008 & 2012

Table 19: Global Other Antibiotics Market by Region for the
Period 2007-2015 (Sales in US$ Million)

Table 20: Percentage Breakdown of Global Other Antibiotics
Market by Region for the Years 2008 & 2012

Table 21: Percentage Breakdown of Leading Antibiotics
Manufacturer Value Sales in the US - 2006

Table 22: Antibiotics Market by Segment in the US: 2007-2015
(Sales in US$ Million)

Table 23: Percentage Breakdown of Antibiotics Market by
Segment in the US for the Years 2008 & 2012

Table 24: Antibiotics Market by Segment in Canada: 2007-2015
(Sales in US$ Million)

Table 25: Percentage Breakdown of Antibiotics Market by
Segment in Canada for the Years 2008 & 2012

Table 26: Antibiotics Market by Segment in Japan: 2007-2015
(Sales in US$ Million)

Table 27: Percentage Breakdown of Antibiotics Market by
Segment in Japan for the Years 2008 & 2012

Table 28: Antibiotics Market by Region in Europe: 2007-2015
(Sales in US$ Million)

Table 29: Percentage Breakdown of Antibiotics Market by Region
in Europe for the Years 2008 & 2012

Table 30: Antibiotics Market by Segment in Europe: 2007-2015
(Sales in US$ Million)

Table 31: Percentage Breakdown of Antibiotics Market by
Segment in Europe for the Years 2008 & 2012

Table 32: Antibiotics Market by Segment in France: 2007-2015
(Sales in US$ Million)

Table 33: Percentage Breakdown of Antibiotics Market by
Segment in France for the Years 2008 & 2012

Table 34: Antibiotics Market by Segment in Germany: 2007-2015
(Sales in US$ Million)

Table 35: Percentage Breakdown of Antibiotics Market by
Segment in Germany for the Years 2008 & 2012

Table 36: Antibiotics Market by Segment in Italy: 2007-2015
(Sales in US$ Million)

Table 37: Percentage Breakdown of Antibiotics Market by
Segment in Italy for the Years 2008 & 2012

Table 38: Antibiotics Market by Segment in the UK: 2007-2015
(Sales in US$ Million)

Table 39: Percentage Breakdown of Antibiotics Market by
Segment in the UK for the Years 2008 & 2012

Table 40: Antibiotics Market by Segment in Spain: 2007-2015
(Sales in US$ Million)

Table 41: Percentage Breakdown of Antibiotics Market by
Segment in Spain for the Years 2008 & 2012

Table 42: Antibiotics Market by Segment in Rest of Europe:
2007-2015 (Sales in US$ Million)

Table 43: Percentage Breakdown of Antibiotics Market by
Segment in Rest of Europe for the Years 2008 & 2012

Table 44: Antibiotics Market by Segment in Asia Pacific:
2007-2015 (Sales in US$ Million)

Table 45: Percentage Breakdown of Antibiotics Market by
Segment in Asia Pacific for the Years 2008 & 2012

Table 46: Antibiotics Market by Segment in Rest of World:
2007-2015 (Sales in US$ Million)

Table 47: Percentage Breakdown of Antibiotics Market by
Segment in Rest of World for the Years 2008 & 2012


COMPANIES PROFILED